Instructions for Arcoxia (Etoricoxib)
Release form
tab, film coating, 30 mg: 14, 28 or 56 units
tab, film coating, 60 mg: 7, 14, 28 or 56 units
tab, film coating, 90 mg: 7, 14, 28 or 56 units
tab, film coating, 120 mg: 7, 14, 28 or 56 units
Description Arcoxia:
Tablets covered with blue-green film, double-convex, apple-shaped, with "ACX 30" embossed on one side and with "101" embossed on the other side; view of the tablet on the cross section: white to pale yellow or white to cream.
1 tab.
Etoricoxib 30 mg
Auxiliary substances: calcium hydrophosphate - 30 mg, cellulose microcrystalline - 37 mg, sodium croscarmellose - 2 mg, magnesium stearate - 1 mg.
Film sheath composition: Opadray II Blue-green 39K11526 - 4 mg, Carnauba wax - 0.01 mg.
The composition of the shell Opadray II Blue-green 39K11526: lactose monohydrate 35%, hypromellose 33%, titanium dioxide 21.19%, triacetine 8%, aluminum lacquer based on indigocarmine dye (E132) 2.41%, iron oxide yellow dye (E172) 0.4%.
14 pcs. - blister packs (1) - cardboard packs.
14 pcs. - blister packs (2) - cardboard packs.
14 pcs. - blister packs (4) - cardboard packs.
ATC codes
M01AH05 Etoricoxib
Clinical-pharmacological groups / Group affiliation
NAPS. Highly selective COX-2 inhibitor
Active substance of the drug
Etoricoxib
Pharmacotherapy group
NSAIDs
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 30 ° C.
Best before date
Shelf life is 3 years. Do not use after expiry date.
Testimony:
- Symptomatic therapy of the following diseases and conditions:
- osteoarthrosis;
- rheumatoid arthritis;
- ankylosing spondylitis;
- Pain and inflammatory symptoms associated with acute suppressive arthritis.
- Short-term treatment of moderate to severe acute pain after dental operations.
Method of use, course and dosage:
The drug is taken inside, regardless of the intake of food, with a little water.
The drug Arcoxia® should be used at the minimum effective dose at the lowest possible short course.
For osteoarthrosis, the recommended dose is 30 mg once/day or 60 mg once/day.
For rheumatoid arthritis and ankylosing spondylitis, the recommended dose is 60 mg or 90 mg 1 time/day. The minimum effective daily dose is 60 mg once/day. In some patients, a dose of 90 mg once/day may lead to an increase in therapeutic effect.
For acute pain conditions, Arcoxia® should only be used during the acute symptomatic period.
For acute podagric arthritis, the recommended dose in the acute period is 120 mg once/day. The duration of use of the preparation in a dose of 120 mg is not more than 8 days.
Acute pain after dental surgery: The recommended dose is 90 mg once per day. In the treatment of acute pain, Arcoxia® should be used only in the acute period of not more than 3 days.
Doses above the recommended values for each indication are either not effective or have not been studied. Thus:
Daily dose for osteoarthrosis should not exceed 60 mg;
Daily dose for rheumatoid arthritis should not exceed 90 mg;
daily dose for ankylosing spondylitis shall not exceed 90 mg;
The daily dose for acute gout arthritis should not exceed 120 mg; for a period not exceeding 8 days;
The daily dose for pain relief after dental surgery should not exceed 90 mg; for a period not exceeding 3 days.
Use in liver disorders
It is contraindicated in severe liver dysfunction.
Patients with mild liver dysfunction (5-6 Child Pugh) and moderate liver dysfunction (7-9 Child Pugh) should be prescribed with caution.
Terms of Sale
The drug is prescription.
Application in elderly patients
Caution should be exercised in the elderly.
Use in children Etoricoxib
The use of the preparation in the age of up to 16 years is contraindicated.
Nosology (ICD codes)
M05
Seropositive rheumatoid arthritis
M10
Podagra
M15
Polyarthrosis
M45
Ankylosing spondylitis
R52.0
Acute pain
R52.2
Other persistent pain (chronic)
